A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination
with immunotherapy in adult patients with advanced cancers. The goal of the study is to
determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc